Loading...

Copyright © 2026

Massachusetts Medical Society.

All rights reserved, including those for text and data mining, AI training, and similar technologies.

Electronic ISSN 3067-1876

The content of this site is intended for health care professionals.

Journals

The New England Journal of Medicine

NEJM Catalyst Innovations in Care Delivery

About

About NEJM Clinician

Editors & Publishers

Editorial Policies

FOLLOW US

Copyright Terms Privacy Policy

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism | NEJM Clinician

NEJM Research Summary

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

New England Journal of Medicine

Mar 11

1 min read

New England Journal of Medicine

March 11

1 min read

New England Journal of Medicine

March 11

1 min read

Related Content

Original Article

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Mar 12

Apixaban vs. Rivaroxaban for Acute VTE: A Clear Safety Winner

New England Journal of Medicine

Mar 11

Topics